<DOC>
	<DOC>NCT01259557</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of Meditoxin® in the treatment of Essential blepharospasm.</brief_summary>
	<brief_title>Efficacy and Safety Study of Meditoxin® to Treat Essential Blepharospasm</brief_title>
	<detailed_description />
	<mesh_term>Blepharospasm</mesh_term>
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Men and women aged above 18 Subjects who was diagnosed with Essential Blepharospasm Subjects who voluntarily Signed written informed consent Subjects who can adhere to protocol and study requirements Subjects with known history of allergy considered due to Botulinum toxin type A Subjects who have received botulinum toxin A type within 3 months Any disease that might affect neuromuscular function (e.g.. Myasthenia Gravis, LambertEaton Syndrome, Amyotrophic Lateral Sclerosis ect.) Subjects who are participating in other clinical trials Pregnant or lactating female Subjects Subjects who are not eligible for the study at the discretion of the Investigator.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>